ba.be-regulatory perspectives by praveen reddy
DESCRIPTION
national seminar at st.peters colg of pharmaceutical sciences on 2nd july 2011TRANSCRIPT
Bioavailability & Bioequivalence:Regulatory perspectives in generic
drug product development
Dr B Praveen ReddyManaging Director
Riconpharma India Pvt LtdHyderabad
(Subsidiary of Riconpharma LLC, NJ, USA)
2nd July 2011
04/09/2023 Riconpharma India 2
Contents• Background information
– Drug development process– Generic drug development
• Bioavailability– Concepts– Factors affecting drug Absorption
• Bioequivalence– Regulatory considerations– Study Designs– Food effect studies
• BCS– Classification– Bio waivers
• Conclusions
04/09/2023 Riconpharma India 3
Drug Approval Process• Average of 10 - 20 years and multi million USD to nurture a drug
from initial discovery to market
Process:
– Academic and Laboratory Research
– Testing done on animals
– Phase 1: Drug given to a small number of healthy people to test its safety
– Phase 2: Drug administered to 100 or more people with the disease that it was intended to treat
– Phase 3: Rigorous testing done on larger groups of ill patients
– FDA Review – Approval/Disapproval
04/09/2023 Riconpharma India 4
NCE development timelines
• 10-20 years time frame• 1 in 10,000 – 100,000 compounds see the market• Very few percentage of market success
– Atorvastatin (Lipitor)– Ranitidine (Zantac)
• High regulatory & ethical hurdles• High R&D costs• Lower effective patent terms• Approved/marketed Priced high to recover costs• High healthcare costs in regulated markets
04/09/2023 Riconpharma India 5
Hatch-Waxman Amendments to FFD&C Act - 1984
• Considered one of the most successful pieces of legislation ever passed
• Created the generic drug industry• Increased availability of generics
• 1984 12% prescriptions were generic• 2000 44% prescriptions were generic - yet only 8% of revenue
for prescription drugs• 2008 >50% genericization
• Compromise legislation to benefit both brand and generic firms
04/09/2023 Riconpharma India 6
Hatch-Waxman Amendments to FFD&C Act - 1984
• Allowed generic firms to rely on findings of safety and efficacy of innovator drug after expiration of patents and exclusivities (do not have to repeat expensive clinical and pre-clinical trials)
• Allowed patent extensions and exclusivities to innovator firms
04/09/2023 Riconpharma India 7
Generics Market
• Generics now account for over 50% of all prescription drugs
• Americans spent over $182.7 billion dollars on prescription drugs in 2002
• The average branded prescription cost four times as much as a generic drug
• Generics save consumers $8 - 10 billion per year
04/09/2023 Riconpharma India 8
Generic drugs• Are safe and effective alternatives to brand name
prescriptions• Can help both consumers and the government reduce
the cost of prescription drugs• Are currently used in more than 50% of all
prescriptions dispensed
04/09/2023 Riconpharma India 9
What are the requirements for a generic drug?
• Same active ingredient(s)
• Same route of administration
• Same dosage form
• Same strength
• Same conditions of approved use
Compared to reference listed drug (RLD) - (brand name product)
Riconpharma India 10
Generic Drug Review Process
Bioequivalence Review
Labeling ReviewChemistry & Micro Review
Request for Plant Inspection
APPLICANT
ANDA
Acceptable & Complete
Application Review
N Chem/Micro
OK?
Labeling
OK?Bioequivalence
OK?
PreApprovalInspection Results
OK?
Not Approvable Letter
Approval Withheld until Results Satisfactory
Bio Deficiency Letter
APPROVED ANDA
NN N
N
Y Y Y
Y
Y
Refuse to Receive Letter
04/09/2023 Riconpharma India 11
Brand Name Drug Generic DrugNDA Requirements ANDA Requirements
1. Chemistry 1. Chemistry2. Manufacturing 2. Manufacturing3. Controls 3. Controls4. Labeling 4. Labeling5. Testing 5. Testing6. Animal Studies7. Clinical Studies 6. Bioequivalence8. Bioavailability
04/09/2023 Riconpharma India 12
How do we assure the quality of generic drugs?
• First 5 steps of review process are identical to NDA process
• Bioequivalence for complicated products is discussed with the same staff that reviewed the brand product
• FDA has experience with the product• Scientific literature published• Product is known to be safe
04/09/2023 Riconpharma India 13
• Bioavailability - Basic Concepts
04/09/2023 Riconpharma India 14
Bioavailability
• The rate and extent of drug absorptionCo
nc.(m
g/L)
Time (h)0 25
0.0
04/09/2023 Riconpharma India 15
Plasma Concentration-Time Profile for a Drug Following a Single Oral Dose
Rate of drug accumulation at any time: dDBODY/dt= dDABS/dt - dDELIM/dt
Absorption Phase:dDABS/dt > dDELIM/dt
At time of peak drug conc.:dDABS/dt = dDELIM/dt
Post-absorption Phase:dDABS/dt < dDELIM/dt
04/09/2023 Riconpharma India 16
The one compartment model linear assumes that the drug in question is evenly distributed throughout the body into a single compartment.
This model is only appropriate for drugs which rapidly and readily distribute between the plasma and other body tissues.
04/09/2023 Riconpharma India 17
Drugs which exhibit a slow equilibration with peripheral tissues, are best described with a two compartment model
04/09/2023 Riconpharma India 18
Absorption is defined as the process by which a drug proceeds from the site of administration to the site of measurement.
Drugs are frequently administered extravascularly oral, sublingual intramuscular, topical, patches,
inhalation Absorption is a
prerequisite for a drug to exert it’s pharmacologic effect (other than local effect)
Several possible sites contribute to the loss
Drug Product
Drug in Blood
Distribution to Tissue and
Receptor sites
MetabolismExcretion
Absorption
Absorption
04/09/2023 Riconpharma India 19
– passive diffusion– active transport– endocytosis– ion-pairing – filtration and bulk flow
Mechanisms of solute transport across membranes
04/09/2023 Riconpharma India 20
A = Passive diffusionB = Active transport/ carrier mediated system
Comparison of the Rates of Drug Absorption
04/09/2023 Riconpharma India 21
Energy Dependent Efflux Transporters – ATP-binding cassette (ABC) proteins
Work against concentration gradientMDR1 (P-glycoprotein)MDR3MRP2 (multidrug resistance
associated protein, cMOAT)BSEP (bile salt export pump)BCRP (breast cancer resistance
protein)
04/09/2023 Riconpharma India 22
How Transporters Affect Bioavailability?
P-glycoproteins expressed in Intestine limit absorption low BA liver increase bile secretion low BAkidney increase secretion in urine shorten t1/2
Brain protect CNS from penetration of toxic
drugs or decrease efficacy of CNS drugsSome lymphocytes drug resistance for HIV drugs
04/09/2023 Riconpharma India 23
Surface area small intestine = 200 m2
stomach = 1 m2
Permeability intestinal membrane>stomach
Blood flow (for perfusion rate-limited absorption) small intestine = 1000 mL/min
through intestinal capillaries stomach = 150 mL/min
Gastric emptying and pH GI transit
Rate of gastric emptying is a controlling step for rapid absorption
Physiological Considerations
04/09/2023 Riconpharma India 24
GIT
04/09/2023 Riconpharma India 25
• The first-pass effect is the term used for the hepatic metabolism of a pharmacological agent when it is absorbed from the gut and delivered to the liver via the portal circulation.
• The greater the first-pass effect, the less the
agent will reach the systemic circulation when the agent is administered orally
First Pass Effect
04/09/2023 Riconpharma India 26
Volume of Distribution The concentration in plasma is achieved after distribution is
complete is a function of dose and extent of distribution of drug into tissues
This extent of distribution can be determined by relating the concentration obtained with a known amount of drug in the body
Concentration is related to the amount by a constant, VOLUME (V)
Amount (mg) = C (mg/L) * V (L) OR V = Amount / C V is known as Apparent Volume of distribution.
Plasma volume ~ 3 L; Extracellular water ~16 L; Total body water ~ 42 L
04/09/2023 Riconpharma India 27
Volume of Distribution Case -1
• At Time zero, the drug amount in the body is the dose (500 mg)
• Calculated drug concentration at Time zero is 50 mg/L• Then, the V = 10 L
Case -2• Dose = 500 mg• Calculated Concentration at time Zero is 5 mg/L• Then, V = 100 L
Examples: Ibuprofen: V is 10 L; Diovan 17 L; Digoxin: ~500L; Chloroquin: 15000 L
04/09/2023 Riconpharma India 28
Drug metabolism/Biotransformation
Liver is the main site of drug metabolism
Extrahepatic:Gut wallIntestinal FloraLungKidney
04/09/2023 Riconpharma India 29
Drug metabolism/biotransformation
This mainly occurs in the liver, via liver enzymes. But it can also occur in the blood plasma or at various
other places (stomach, intestines, lungs, skin, or kidneys) directly by various enzymes at those locations
In any case, these metabolites are then excreted/eliminated (more easily than would the parent molecule have been) metabolites are often smaller in size, ionized
Some drugs are excreted/eliminated in un-metabolized form, as the original drug molecule
04/09/2023 Riconpharma India 30
Reactions Catalysed by Drug metabolizing enzymes
Oxidative reactions (Phase I)dealkylationhydroxylationoxidation Deamination
Conjugation reactions (Phase II)glucuronidationglutathione conjugationsulfationacetylation
04/09/2023 Riconpharma India 31
Genetic (polymorphism in expression of enzymes in a population)
CYP2D6, CYP2C19, NAT2, etc.
Environmental (food, smoking) Grapefruit juice (↑AUC and ↑Cmax)
Drug-Drug interaction Inhibition (↑AUC and ↑Cmax)
Induction (↓AUC and ↓Cmax)
Age
Disease (hepatic impairment)
How Drug Metabolism Affects Bioavailability?
04/09/2023 Riconpharma India 32
Excretion The Kidneys
This is the main excretory organ for drugsThe Nephron: Glomerulus, proximal
tubule, loop of Henle, distal tubule, and collecting tubule
Drug enters the lumen of the nephron by filtration and secretion
Filtration occurs in the glomerulus; secretion is primarily restricted to the proximal tubules
Reabsorption occurs all along the nephron; Active reabsorption usually occurs in the proximal tubule
Appearance of drug in the urine is the net result of filtration, secretion, and reabsorption
04/09/2023 Riconpharma India 33
Other Routes of Excretion/Elimination
In bile (which then empties into gut, excreted in feces)[can excrete from 5 to 95% of drug dose, esp. antibiotics]
In sweat, saliva, tears, exhaled breath, milk, hair, nails[as heart rate increases --- pulmonary circulation --- which then increases amounts of breath exhaled --- more drug eliminated]
04/09/2023 Riconpharma India 34
Clearance
Quantifies Elimination
Is the volume of body fluid cleared per time unit (L/h, mL/min)
04/09/2023 Riconpharma India 35
Why is Clearance Important?
Clearance is the one parameter that determines the maintenance dose rate required to achieve a desired plasma conc.
Dosing rate = clearance X desired plasma conc.
04/09/2023 Riconpharma India 36
Area Under the Concentration – Time Curve (AUC)
A quantitative measure for exposure from dosing time to time ‘t’
An important parameter in PK AUC(t) and AUC(inf) Determined by trapezoidal method AUC(inf) = AUC(t) + Ct/k
Units: Conc*t (mg/L * h) Proportional to Dose (linear PK) Accuracy of the estimate depends
on frequency of sampling
0.01
0.1
1
10
0 5 10 15 20
Time (hr)
Con
cen
trati
on
(U
nit
s/m
l)
Area Under the Curve (AUC)
04/09/2023 Riconpharma India 37
Concept of “Half Life” ½ life = how much time it takes for blood levels of drug to decrease
to half of what it was at equilibrium There are really two kinds of ½ life…
“distribution” ½ life = when plasma levels fall to half what they were at equilibrium due to distribution to/storage in body’s tissue reservoirs
“elimination” ½ life = when plasma levels fall to half what they were at equilibrium due to drug being metabolized and eliminated
It is usually the elimination ½ life that is used to determine dosing schedules, to decide when it is safe to put patients on a new drug
04/09/2023 Riconpharma India 38
04/09/2023 Riconpharma India 39
“Rule of Five”
5x the elimination ½ life = time at which the drug is “completely” (97%) eliminated from the body 1x ½ life - 50% of the original drug removed2x ½ life - 75%3x ½ life - 87.5%4x ½ life - 93.75%5x ½ life - 96.875%
04/09/2023 Riconpharma India 40
Barriers to Oral Delivery and Systemic Exposure
Drug Free Drug
Bound Drug
Target
Systemic CirculationGut Liver
FormulationSolubility
Permeability
First Pass Metabolism
Protein Binding
04/09/2023 Riconpharma India 41
Interactions in Oral Drug Absorption
04/09/2023 Riconpharma India 42
Physico-Chemical Factors
Partition coefficient
Ionization, pH-pKa Relationship
Intrinsic solubility
Polymorphism
Particle Size
Salt form
04/09/2023 Riconpharma India 43
BA/BE - Regulatory considerations
04/09/2023 Riconpharma India 44
Bioavailability (BA)
• Bioavailability is defined in CFR § 320.1 as:• the rate and extent to which the active
ingredient or active moiety is absorbed from a drug product and becomes available at the site of action.
– For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action.
04/09/2023 Riconpharma India 45
Why BA study?
• To establish dose response relationship• To assess extent of drug absorption with reference to
IV dosing• To derive information on ADME• To establish dose linearity• To assess dosage form functionality• To assess the performance of the formulations used in
the clinical trials that provide evidence of safety and efficacy (21 CFR 320.25(d)(1)).
• To assess Relative BA (Bioequivalence)
04/09/2023 Riconpharma India 46
Bioequivalence
• Bioequivalence is defined in CFR § 320.1 as:• “the absence of a significant difference in the
rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study”
04/09/2023 Riconpharma India 47
Pharmaceutical Equivalents
• Drug products are considered pharmaceutical equivalents if they contain the same active ingredient(s), have the same dosage form and route of administration, and are identical in strength or concentration
• Equivalent products contain the same amount of ingredient in the same dosage form but may differ in characteristics, such as shape, release mechanisms, excipients and packaging– Patent challenge opportunities– Freedom of research within regulatory boundaries
04/09/2023 Riconpharma India 48
Pharmaceutical Alternatives
• Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, are different salts, esters, or complexes of the same moiety, are different dosage forms, or are different strengths
• Other pharmaceutical alternatives– Different dosage forms and strengths within a single
product line by a single manufacturer– Extended-release formulations when compared with
immediate- or standard-release formulations
04/09/2023 Riconpharma India 49
Therapeutic Equivalents
• Drug products are considered therapeutic equivalents if they are all of the following– Pharmaceutical equivalents– Bioequivalent– Approved as safe and effective– Adequately labeled– Manufactured in compliance with current Good
Manufacturing Practice regulations• Therapeutic equivalents are expected to have the
same clinical effect and safety profile
04/09/2023 Riconpharma India 50
Use of Bioequivalence to Determine Therapeutic Equivalency
• There is a strong correlation between single-dose pharmacokinetics and therapeutic effects
• Single-dose pharmacokinetics are similar to steady-state pharmacokinetics
• Patients have a pharmacokinetic profile comparable to that of healthy volunteers
• A –20% to +20% difference in drug absorption of two pharmaceutical equivalent products has no significant effect on therapeutic outcomes
04/09/2023 Riconpharma India 51
BE relevance in regulatory framework
• 1. IND/ NDA (Original product)– BE documentation can be useful during the IND or NDA
approval/review period to establish links between – (1) early and late clinical stage trial formulations; – (2) formulations used in clinical trial and stability studies, if
different; – (3) clinical trial formulations and to-be-marketed drug
product; (In each of the above comparison, the new formulation or new method of manufacture is the test product and the prior formulation or method of manufacture is the reference product)
04/09/2023 Riconpharma India 52
BE relevance in regulatory framework
IND/NDA (contd..)• Where the test product generates plasma levels that are
substantially above those of the reference product, the regulatory concern is not therapeutic failure, but the adequacy of the safety database from the test product.
• Where the test product has levels that are• substantially below those of the reference product, the
regulatory concern becomes therapeutic efficacy
• When the variability of the test product rises, the regulatory concern relates to both safety and efficacy
04/09/2023 Riconpharma India 53
BE relevance in regulatory framework
• 2. ANDAs (Generic drug products)– BE studies are a critical component of ANDA submissions. – The purpose of these studies is to demonstrate BE between
a pharmaceutically equivalent generic drug product and the corresponding reference listed drug (21 CFR 314.94 (a)(7)).
– Together with the determination of pharmaceutical equivalence, establishing BE allows a regulatory conclusion of therapeutic equivalence
• Inter changeability with innovator products (equivalence ratings in Orange Book)
• Opened up generics market• Significant reduction in healthcare costs for all stake holders
04/09/2023 Riconpharma India 54
BE relevance in regulatory framework
• 3. Post approval changes– certain major changes in
• components, composition, and/or method of manufacture after approval
• change in site of manufacture• major change in equipment / manufacturing process
– Reduces cost of approval process/ time(SUPAAC-IR & MR guidance documents details the requirements
of BE studies based on level of changes being effected)
04/09/2023 Riconpharma India 55
Methods to document BA/BE
– PK studies– PD studies– Comparative clinical studies– In-vitro studies
• BCS class I
Order of preference
04/09/2023 Riconpharma India 56
PK studies
• This approach rests on an understanding
– that measuring the active moiety or ingredient at the site of action is generally not possible
– that some relationship exists between the efficacy/safety and concentration of active moiety and/or its important metabolite or metabolites in the systemic circulation.
04/09/2023 Riconpharma India 57
PK studies• To measure product quality BA and establish BE, reliance on
pharmacokinetic measurements may be viewed as a bioassay that assesses release of the drug substance from the drug product into the systemic circulation.
• A typical study is conducted as a crossover study.
• In this type of study, clearance, volume of distribution, and absorption, as determined by physiological variables (e.g. gastric emptying, motility, pH), are assumed to have less inter occasion variability compared to the variability arising from formulation performance
04/09/2023 Riconpharma India 58
PK studies
• 1. Pilot BE study– small number of subjects – The study can be used to validate analytical
methodology, assess variability, optimize sample collection time intervals, sample size etc.,
• 2. Pivotal BE study– Submission to regulatory agency– Conducted as per approved protocol
04/09/2023 Riconpharma India 59
PK study design• Non replicate 2-way cross over design, fast/fed
– IR dosage forms– MR dosage forms (single/ multiple dose)– More sensitive– Most preferred– Truncated design for drugs with long elimination half life
• Replicate design– Suitable for drug products with likely high intra subject variability– Requires less number of subjects– Understands subject by formulation variations better– More expensive
• parallel design – For long half life drugs
• Analyte: Parent/ metabolite/ pro-drug• Bio analytical methods
– Validated– LC MS-MS
04/09/2023 Riconpharma India 60
PK parameters
1. Statistical treatment1. Cmax2. AUC 0-t3. AUC 0-inf
2. Informative1. Tmax2. Kel3. Half-life4. Geometric/ arithmetic means of relevant PK
parameters
04/09/2023 Riconpharma India 61
Statistical Basis
• Bioequivalence criteria– Two one-sided tests procedure– Log-transformed data– 90% confidence interval– Significant difference is 20% (alpha is 0.05)– Test (T) is not significantly less than Reference (R)– Reference (R) is not significantly less than Test (T)– T/R = 80/100 * 100 = 80%– R/T = 100/80 * 100 = 125%
• BE Acceptance criteria: 80.00 – 125.00 of T/R (%) for Cmax, AUC0-t, AUC0-inf at 90% CI
04/09/2023 Riconpharma India 62
Possible BE Results (90% CI)
T/R (%)80% 125%
04/09/2023 Riconpharma India 63
Effect of a Change in Absorption Rate Constant (Ka) on Plasma Drug Concentration Versus Time Curve
0.5/hr
0.2/hr
04/09/2023 Riconpharma India 64
Rate vs extent of absorption (rate varies)
04/09/2023 Riconpharma India 65
Rate vs extent of absorption (extent varies)
04/09/2023 Riconpharma India 66
Formulation Variables affecting absorptive phase
• Drug release – pH release profile across GIT– Release mechanism– Excipients– Functional coatings– Method of manufacture
• Dosage form – Rapidly disintegrating– Swelling/ muco adhesive nature
04/09/2023 Riconpharma India 67
Bioequivalence: IR Products
Reference Test
Pharmaceutical EquivalentProducts
Possible Differences
Drug particle size, ..
Excipients
Manufacturing process
Equipment
Site of manufacture
Batch size ….
Documented Bioequivalence= Therapeutic Equivalence
(Note: Generally, same dissolution spec.)
Normal healthy subjectsCrossover design
Overnight fastGlass of water
90% CI within 80-125%of Ref. (Cmax & AUC)
04/09/2023 Riconpharma India 68
“Orange Book”• US FDA Official publication – “Approved Drug Products with Therapeutic equivalence
Evaluations”• Reference document to healthcare professionals/ insurance/ patients• Lists all approved products for US market
– (NDA’s, OTC’s & ANDA’s)• Lists approved generic drug products with suitable Therapeutic equivalence ratings
“A” = Substitutable “B” = Inequivalent, NOT Substitutable “AB” = Therapeutic equivalents demonstrated through appropriate BE study
• Reference Listed Drugs/brand drugs identified by FDA for generic companies to compare with their proposed products
• Lists the strength(s) for which BE to be established, referred to as “RLD”• RLD is usually higher strength
– RLD as lower strength due to safety considerations• Contains patent and exclusivity information
– Patent challenge opportunities
04/09/2023 Riconpharma India 69
FDA recommendations
• Individual BE study recommendations– RLD– Study design– Analytes– Bio-waiver recommendations for lower strengths
• Individual dissolution recommendations– Apparatus type, rpm– Medium/ volume– Recommended sampling time points
04/09/2023 Riconpharma India 70
Documentation for BE
• An in vivo study is generally recommended for – all solid oral dosage forms approved after 1962– and for bio problem drug products approved
before 1962. (DESI products)– Required for all suspension oral dosage forms
04/09/2023 Riconpharma India 71
Documenting BE-Solid orals
• For product quality BA and BE studies, – focus is on release of the drug substance from the drug
product into the systemic circulation, – a single-dose, fasting study be performed. – BE studies be accompanied by in vitro dissolution profiles on
all strengths of each product. • IVIVC/ relevant dissolution spec
• For ANDAs, – BE study to be conducted between the test product and
reference listed drug (RLD) using the strength(s) specified in Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
04/09/2023 Riconpharma India 72
Documenting BE-solutions
• For oral solutions, elixirs, syrups, tinctures, or other solubilized forms, in vivo BA and/or BE can be waived (21 CFR 320.22(b)(3)(i)).
• Generally, in vivo BE studies are waived for solutions on the assumption that release of the drug substance from the drug product is self-evident and that the solutions do not contain any excipient that significantly affects drug absorption (21 CFR 320.22(b)(3)(iii)).
• However, there are certain excipients, such as sorbitol or mannitol, that can reduce the bioavailability of drugs with low intestinal permeability in amounts sometimes used in oral liquid dosage forms
04/09/2023 Riconpharma India 73
Documentation of BE
• Bio-waivers– Applicable for NDAs/ ANDAs– Waiver of in vivo studies for different strengths of a drug
product can be granted under § 320.22(d)(2) when • (1) the drug product is in the same dosage form, but in a
different strength; • (2) this different strength is proportionally similar in its active
and inactive ingredients to the strength of the product for which the same manufacturer has conducted an appropriate in vivo study; and
• (3) the new strength meets an appropriate in vitro dissolution test.
04/09/2023 Riconpharma India 74
Documentation of BE (contd..)
• Proportionally similar means– Applicable to multiple strength drug product
– All active and inactive ingredients are in exactly the same proportion between different strengths
– Active and inactive ingredients are not in exactly the same proportion between different strengths as stated above, but the ratios of inactive ingredients to total weight of the dosage form are within the limits defined by the SUPAC-IR and SUPAC-MR guidances
04/09/2023 Riconpharma India 75
Food effect studies
• Food effect BA studies are usually conducted for – new drugs – drug products during the IND period
• to assess the effects of food on the rate and extent of absorption of a drug when the drug product is administered shortly after a meal (fed conditions), as compared to administration under fasting conditions.
• Fed BE studies, are conducted for ANDAs – to demonstrate their bioequivalence to the reference
listed drug (RLD) under fed conditions
04/09/2023 Riconpharma India 76
Why Food effect studies?
• Food can alter BA by various means, including– Delay gastric emptying– Stimulate bile flow– Change gastrointestinal (GI) pH– Increase splanchnic blood flow– Change luminal metabolism of a drug substance– Physically or chemically interact with a dosage
form or a drug substance
04/09/2023 Riconpharma India 77
Food effect studies- Exceptions
• When both test product and RLD are – rapidly dissolving, – have similar dissolution profiles, – and contain a drug substance with high solubility and high
permeability (BCS Class I) or• When the DOSAGE AND ADMINISTRATION section of
the RLD label states that the product should be taken only on an empty stomach, or
• When the RLD label does not make any statements about the effect of food on absorption or administration
04/09/2023 Riconpharma India 78
Food effect BE study• Test meal
– Recommended that food-effect BA and fed BE studies be conducted using meal conditions that are expected to provide the greatest effects on GI physiology so that systemic drug availability is maximally affected.
– A high-fat (approximately 50 percent of total caloric content of the meal) and
– high-calorie (approximately 800 to 1000 calories) meal is recommended as a test meal
– This test meal should derive approximately 150, 250, and 500-600 calories from protein, carbohydrate, and fat, respectively.
• Typical meal– two eggs fried in butter, two strips of bacon, two slices of toast with butter,
four ounces of hash brown potatoes and eight ounces of whole milk.• Special studies: Apple sauce/ beverages etc.,
04/09/2023 Riconpharma India 79
The Biopharmaceutics Classification System (BCS)
04/09/2023 Riconpharma India 80
Purpose of the BCS guidance
• Expands the regulatory application of the BCS and recommends methods for classifying drugs
• Explains when a waiver for in vivo bioavailability and bioequivalence studies may be requested based on the approach of BCS– Intention to minimize human exposure – To simplify and expedite regulatory approval
process
04/09/2023 Riconpharma India 81
Biopharmaceutics Classification System (BCS)
04/09/2023 Riconpharma India 82
Class Boundaries
Drug Substance:
-is considered HIGHLY SOLUBLE when the highest dose strength is soluble in < 250 ml water over a pH range of 1 to 7.5.
-is considered HIGHLY PERMEABLE when the extent of absorption in humans is determined to be > 90% of an administered dose, based on mass-balance or in comparison to an intravenous reference dose.
drug product:- is considered to be RAPIDLY DISSOLVING when > 85% of
the labeled amount of drug substance dissolves within 30 minutes
using USP apparatus I or II in a volume of < 900 ml buffer solutions.
04/09/2023 Riconpharma India 83
Solubility Determination
pH-solubility profile of test drug in aqueous media with a pH range of 1 to 7.5.
Shake-flask or titration method.
Analysis by a validated stability-indicating assay.
04/09/2023 Riconpharma India 84
Permeability Determination
Extent of absorption in humans: Mass-balance pharmacokinetic studies. Absolute bioavailability studies.
Intestinal permeability methods: In vivo intestinal perfusions studies in humans. In vivo or in situ intestinal perfusion studies in
animals. In vitro permeation experiments with excised
human or animal intestinal tissue. In vitro permeation experiments across
epithelial cell monolayers.
04/09/2023 Riconpharma India 85
Determining Drug Product Dissolution Characteristics and Dissolution Profile Similarity
Dissolution testing should be carried out in USP Apparatus I at 100 rpm or Apparatus II at 50 rpm using 900 ml of the following dissolution media: 0.1N HCl or Simulated Gastric Fluid USP
without enzymesa pH 4.5 buffera pH 6.8 buffer or Simulated Intestinal
Fluid USP without enzymes
For capsules and tablets with gelatin coatingSimulated Gastric and Intestinal Fluids USP
(with enzymes) can be used.
04/09/2023 Riconpharma India 86
Dissolution Profile Similarity
A minimum of 12 dosage units of a drug product should be evaluated to support a biowaiver request.
Samples should be collected at a sufficient number of intervals to characterize the dissolution profile of the drug product (e.g., 10, 15, 20, and 30 minutes).
When comparing the test and reference products, dissolution profiles should be compared using a similarity factor (f2). The similarity factor is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent (%) of dissolution between the two curves.
f2 = 50 * log {[1+(1/n)*t=1n (Rt - Tt)2]-0.5 * 100}
Two dissolution profiles are considered similar when the f2 value is 50. Note: When both test and reference products dissolve 85% or more of the label amount of the drug in 15 minutes using all three dissolution media recommended above, the profile comparison with an f2 test is unnecessary.
04/09/2023 Riconpharma India 87
Conditions for BCS Bio-waivers
Firms can request waivers of in vivo testing for Class 1 drug substances Drug products must meet these criteria: Immediate-release solid oral dosage formsHighly soluble, highly permeable drug
substanceRapid in vitro dissolution
Note: Waivers not applicable for narrow therapeutic range therapeutic range (Digoxin, Lithium, phenytoin, warfarin) drugs
04/09/2023 Riconpharma India 88
Predictability of high-fat meal effects by BCS Class
Wu & Benet, Pharm Res, 2005 after Fleisher et al, CPK, 1999
04/09/2023 Riconpharma India 89
Wu & Benet, Pharm Res, 2005
Transport Effect on Drug PK by BCS Class
04/09/2023 Riconpharma India 90
Conclusions
• BA/BE studies play a key role in regulatory approval process of – NDAs / ANDAs / Post-approval Changes
• Expedites approvals• Reduces cost of proving therapeutic
equivalence• Paves way for bio waivers
04/09/2023 Riconpharma India 91
Acknowledgements
• Highly thankful to research scholars/ scientists representing US FDA, Academic institutions, Pharmaceutical Industries for making available the content
Thank you ……
Please contact for additional details:
Dr B Praveen ReddyManaging Director
Riconpharma India Private LimitedPlot No. 113 & 114, II FloorALEAP Industrial EstatePragathinagar, KukatpallyHyderabad 500 072 INDIAPh: +91 40 20040386 (Office) +91 9652969669 (Cell)www.riconpharma.com